Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

Is retatrutide FDA approved?

No, as of 2026, retatrutide has not yet been approved by the FDA or EMA. It is currently undergoing Phase 3 clinical trials focusing on safety and efficacy markers including weight-loss, liver fat reduction, and dysesthesia tracking.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide For Obstructive Sleep Apnea Triumph Trial Results

Retatrutide for obstructive sleep apnea TRIUMPH trial results are eagerly awaited from Eli Lilly's Phase 3 program, with no specific OSA data released yet but strong proxies from related trials.[1][2] The TRIUMPH basket trials test this triple agonist in over 5,800 participants, focusing on obesity comorbidities like OSA through nested protocols in TRIUMPH-1 and TRIUMPH-2.[1][2][3] Early topline from TRIUMPH-4 shows 28.7% weight loss at 12 mg, hinting at potential AHI improvements via substantial fat reduction.[4]

Introduction to Retatrutide for Obstructive Sleep Apnea

Retatrutide represents a promising investigational therapy for obstructive sleep apnea (OSA), a condition affecting millions where breathing repeatedly stops during sleep due to airway blockage. Developed by Eli Lilly,[1][2] this weekly injection targets obesity—the key driver of OSA in most cases—through a unique mechanism.[3] Retatrutide for obstructive sleep apnea TRIUMPH trial results could redefine treatment by addressing root causes rather than just symptoms.

What is Retatrutide? Triple Agonist Mechanism

Retatrutide is a retatrutide triple agonist mechanism that activates three receptors: GLP-1, GIP, and glucagon.[3] GLP-1 and GIP curb hunger and slow digestion, much like semaglutide or tirzepatide. The added glucagon boosts energy use and fat burning for superior results.[3]

This combination led to 24% weight loss in Phase 2 trials.[3] The glucagon component also aids liver fat reduction, as detailed in glucagon benefits in retatrutide mechanism. For basics, visit Eli Lilly's retatrutide page.

Link Between Obesity, OSA, and Retatrutide's Potential

Over 70% of OSA cases link to obesity, where neck and tongue fat collapses airways. Losing just 10% body weight can cut apnea-hypopnea index (AHI)—pauses per sleep hour—by 26%. Retatrutide's aggressive fat loss positions it to excel here.

Studies show weight drugs improve OSA even without full resolution. Retatrutide for obstructive sleep apnea TRIUMPH trial results may quantify this, offering alternatives to masks or surgery. This tackles daytime fatigue, heart risks, and poor quality of life.

Overview of the TRIUMPH Phase 3 Program

TRIUMPH spans four double-blind trials versus placebo, plus diet and exercise, enrolling over 5,800 with BMI ≥30 (or ≥27 with issues).[1][2] Duration: 68-89 weeks.[1][2][4] Primary goal: weight change percent.[1]

Basket design nests conditions like OSA.[1][2] TRIUMPH-1/2 focus obesity with OSA subsets; TRIUMPH-3 cardiovascular; TRIUMPH-4 knee OA.[1][2][4] Track via ClinicalTrials.gov NCT05929066.[1]

Understanding the TRIUMPH Clinical Trial Program

This Phase 3 effort uses basket trials to efficiently study obesity-linked diseases.[1][2] Participants qualify via BMI and comorbidities; exclusions include severe heart issues or cancer history. Doses titrate slowly: start 2.5 mg, up to 4, 9, or 12 mg weekly.[2][4]

Basket Trial Design: TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4

TRIUMPH-1/2: Core weight management with OSA/OA nests (~2,300 total).[1][2]
TRIUMPH-3: CVD patients needing weight control.[2]
TRIUMPH-4: OA-specific, topline December 2025.[4]

One trial tests multiple groups, sharing obesity data. See Lilly's TRIUMPH announcement.[2]

Enrollment, Duration, and Primary Endpoints

5,800+ enrolled globally.[1][2] TRIUMPH-1/2: 89 weeks, weight loss primary.[1] OSA adds AHI via sleep studies.[1]

Secondary: blood pressure, lipids, sleepiness (ESS score). Eligibility: adults 18+, OSA confirmed by AHI ≥15.

ClinicalTrials.gov Details (NCT05929066)

NCT05929066 is the obesity master protocol; OSA nests under it.[1] Status: active, results 2026.[1] Search "TRIUMPH retatrutide" for sites. Updates note maintenance 4 mg testing.[2]

Retatrutide's Role in TRIUMPH-1 and TRIUMPH-2 for OSA

These trials embed OSA in obesity studies, assessing retatrutide for obstructive sleep apnea TRIUMPH trial results directly.[1][2] Patients get polysomnograms (sleep tests) at start, week 40, and 80. Combo with lifestyle aims sustained change.

Nested Protocols for Obesity with Obstructive Sleep Apnea

OSA subset: BMI ≥27-30, AHI ≥15, no CPAP intolerance.[1] Measures beyond weight: oxygen levels, awakenings. Design mirrors real comorbid cases.[2]

Doses Tested: 4 mg Maintenance, 9 mg, and 12 mg

4 mg: Long-term option (data pending).[2]
9/12 mg: High-efficacy, from TRIUMPH-4.[4]

Titration: 4 weeks per step, minimizing nausea.

Trial Status: Ongoing with Results Expected in 2026

Recruiting complete; topline mid-2026.[1][2] Delays from analysis possible.

TRIUMPH-4 Topline Results: Insights Relevant to OSA

Though OA-focused, TRIUMPH-4 (68 weeks, ~2,300) proxies OSA via 28.7% loss.[4] No diabetes patients.[4] Announced December 11, 2025.[4]

Endpoint	12 mg	9 mg	Placebo
Weight Loss	-28.7% (32.3 kg)	Significant	-2.1%
WOMAC Pain	-75.8%	-67.2%	-35.1%
Pain-Free	>12%	Notable	4.2%

Details in TRIUMPH-4 28.7% weight loss topline results.

Weight Loss Achievements: 28.7% at 12 mg Dose

Placebo-adjusted: 26.6%.[4] Beats tirzepatide (22.5%), semaglutide (14.9%).[3][4] For OSA, this scale predicts big AHI drops.

Knee OA Pain Reduction on WOMAC Scale

-4.5 points at 12 mg.[4] Function up, CV markers down. See knee OA pain relief in TRIUMPH-4.

Comparisons to Semaglutide and Tirzepatide

Triple vs. dual/single: more loss, similar safety.[3][4] Phase 2 head-to-head favors retatrutide.[3]

Expected Efficacy Results for OSA in TRIUMPH Trials

Retatrutide for obstructive sleep apnea TRIUMPH trial results target key metrics. Prior GLP-1s like tirzepatide hit 40-50% AHI responders; retatrutide may top via deeper loss.

Key OSA Endpoints: AHI Reduction and ESS Scores

≥50% AHI drop.
AHI <5 (cure-like) or 5-14 + ESS ≤10 (mild, non-sleepy).[1]

Week 80 polysomnography.[1] Matches FDA OSA criteria.

Percentage Achieving ≥50% AHI Reduction at Week 80

Projections: 60%+ at 12 mg, based on 10% loss = 26% AHI cut. Baseline AHI 30-50 common.

Weight Loss as Proxy for OSA Improvement

28% loss could normalize AHI in many.[4] Adds ESS, quality-of-life scores.

Safety Data and Side Effects from TRIUMPH Trials

GI common (nausea 40-50%), transient. Heart rate +5-10 bpm. Retatrutide for obstructive sleep apnea TRIUMPH trial results will detail OSA safety.

Emerging Signal: Dysesthesia at Higher Doses

Altered skin sensations at 9-12 mg.[4] Mild, but new. Strategies in managing retatrutide dysesthesia at 12 mg.

Discontinuation Rates: 12.1% at 12 mg (BMI ≥35)

12.1% (12 mg), 8.8% (9 mg) vs. 4.8% placebo.[4] OSA data pending.

Comparison to Placebo and Prior Phases

Matches Phase 2; no red flags.[3][4] Monitor thyroid, pancreas per class.

Current Clinical Trial Status and FDA Approval Outlook

Investigational; trials only.[1][2] No home use.

Investigational Status: Not FDA Approved

Phase 3 ongoing.[1][2] Obesity first.

Legal Availability: Clinical Trials Only

Eligibility: obese OSA adults.[1] Sites via ClinicalTrials.gov.[1]

Timeline for Full Data and NDA Submission

2026 OSA data.[1][2] See TRIUMPH trials completion dates and NDA impact and retatrutide NDA submission timeline. NDA late 2026, approval 2027+.

Future Implications and Next Steps for Retatrutide in OSA

Positive data could add OSA label. Beats CPAP adherence (50%). Vs. surgery: less invasive.

Potential for OSA Label Expansion

Root-cause fix. Combo therapies next.

Peer-Reviewed Publications and Medical Meetings

2026: ADA, ATS. NEJM expected.[3]

Comparisons to Existing OSA Treatments

CPAP: Effective but disliked.
Oral devices: Mild OSA.
Retatrutide: Weekly shot, metabolic bonus.

Conclusion: What TRIUMPH Means for OSA Patients

Retatrutide for obstructive sleep apnea TRIUMPH trial results promise a breakthrough, with 2026 data pivotal.[1][2] TRIUMPH-4's weight loss and comorbidity wins build case for AHI/ESS gains.[4] Safety manageable despite dysesthesia.[4]

Patients: discuss trials, lifestyle now. Watch FDA path. This could ease OSA burden for obese majority, expanding beyond devices. Consult providers; stay informed via Lilly updates.